Opportunity Information: Apply for PAS 06 261
Apply for PAS 06 261
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Grants for Alzheimers Disease Drug Discovery (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.866 Aging Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Mar 24, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education For profit organizations other than small businesses Independent school districts Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public housing authorities/Indian housing authorities County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments State governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Grants for Alzheimers Disease Drug Discovery (R21) (Funding Opportunity Number PAS-06-261) is a National Institutes of Health (NIH) funding opportunity created under the broader Alzheimers Disease (AD) Prevention Initiative that began in 1999 at the direction of Congress. The initiative is led by the National Institute on Aging (NIA) in collaboration with several other NIH institutes, including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR). The main purpose behind this program is to speed up the movement of promising basic science findings into later-stage work that can ultimately support clinical trials for Alzheimers treatment and prevention. Within that larger pipeline, this specific announcement focuses on the earlier end of translation: drug discovery and early preclinical testing, while related companion announcements address later steps such as drug development and pilot clinical trials.
The research scope is centered on identifying and testing novel compounds aimed at preventing or treating the cognitive impairment and behavioral symptoms associated with Alzheimers disease. Applicants are encouraged to propose projects that include discovery activities and preclinical evaluation using cellular systems, tissue-based models, and animal models. In practical terms, this means the program is designed to support work like finding new therapeutic targets or pathways, identifying candidate molecules, optimizing or characterizing lead compounds in early-stage testing, and generating the type of biological proof-of-concept data that would justify more advanced development efforts later on. The announcement emphasizes translation-oriented science, meaning proposals should be positioned to move beyond purely descriptive biology and toward interventions that can eventually be tested in people, even if the work funded here remains preclinical.
The award mechanism is the NIH Exploratory/Developmental Grant (R21), which is intended for early, high-impact, and potentially higher-risk projects that are still in conceptual or exploratory stages. R21 projects are generally expected to be focused and milestone-driven, producing clear feasibility or proof-of-principle data rather than completing a full mature development program. Awards may last up to two years, and applicants may request up to $275,000 in direct costs total across the two-year period. The announcement notes that award sizes and the number of awards can vary depending on the scientific merit, project duration, and requested costs across the pool of applications. Importantly, R21 awards under this program are not renewable, so the expectation is that successful projects would use the R21 as a launch point for subsequent applications through other mechanisms if the early findings are strong.
On the funding side, NIA indicated it set aside an estimated $3.0 million in total costs in FY 2006 to support applications submitted in response to this program announcement. Applications are reviewed using the standard NIH peer review process and assigned to the appropriate participating NIH Institute or Center (IC) based on standard Public Health Service (PHS) referral guidelines and program relevance. Funding decisions are made by the assigned NIH IC, and in some cases meritorious applications may be co-funded by the assigned NIH institute together with the Institute for the Study of Aging (ISOA), which is mentioned as a potential co-funder for strong proposals.
Eligibility is broad and includes for-profit and nonprofit organizations, as well as public or private institutions such as universities, colleges, hospitals, and laboratories. Government entities are also eligible, including eligible federal agencies, state governments, and local governments. Both domestic and foreign institutions may apply, which is notable because some federal opportunities restrict awards to U.S.-based institutions only. The eligible applicant list also explicitly includes a wide range of organizational types (for example, institutions of higher education, certain nonprofit categories, and various local governmental bodies). There is no cost sharing or matching requirement.
For project leadership, the opportunity is open to any individual with the skills, knowledge, and resources needed to carry out the proposed research, working through an eligible institution. Consistent with NIH-wide policy goals, the announcement encourages applications from individuals from underrepresented racial and ethnic groups and from individuals with disabilities. Applicants are allowed to submit more than one application as long as the applications are scientifically distinct, meaning they do not overlap substantially in aims, approach, or proposed outcomes.
Key administrative details include that the opportunity was posted March 24, 2006, has multiple receipt dates (rather than a single deadline), and was later archived (archive date June 1, 2009). The announcement is categorized as a discretionary grant opportunity in the health domain and is associated with multiple CFDA numbers reflecting the cross-institute nature of the topic area (aging research, neurosciences/neurological disorders, and mental health research). The full announcement link provided is http://grants.nih.gov/grants/guide/pa-files/PAS-06-261.html, and general technical support for accessing the notice is routed through the NIH Office of Extramural Research (OER) webmaster contact listed in the source text.
Frequently Asked Questions (FAQs)
What is the Grants for Alzheimers Disease Drug Discovery (R21) opportunity?
This funding opportunity, PAS-06-261, is a National Institutes of Health (NIH) program announcement that supports exploratory research focused on Alzheimers disease (AD) drug discovery and early preclinical testing.
Which federal agency runs this program?
The program is part of the NIH. It is led by the National Institute on Aging (NIA) in collaboration with other participating NIH institutes, including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR).
How does this opportunity fit into the broader Alzheimers Disease Prevention Initiative?
The opportunity sits within the broader Alzheimers Disease (AD) Prevention Initiative that began in 1999 at the direction of Congress. The overall initiative aims to speed translation of basic science findings toward clinical trials for AD treatment and prevention. This specific announcement focuses on earlier-stage translation (drug discovery and early preclinical testing), while companion announcements address later steps such as drug development and pilot clinical trials.
What is the main purpose of the program?
The purpose is to accelerate translation-oriented research by moving promising findings toward interventions that could later support clinical trials for Alzheimers treatment or prevention, even though the work supported here is at the drug discovery and early preclinical stage.
What types of research are in scope?
The scope centers on identifying and testing novel compounds intended to prevent or treat cognitive impairment and behavioral symptoms associated with Alzheimers disease. Projects are encouraged to include both discovery activities and preclinical evaluation.
What models or systems can be used for the preclinical evaluation?
The announcement highlights preclinical evaluation using cellular systems, tissue-based models, and animal models.
What kinds of activities does NIH expect applicants to propose?
Examples described in the announcement include identifying new therapeutic targets or pathways, identifying candidate molecules, optimizing or characterizing lead compounds in early-stage testing, and generating biological proof-of-concept data that could justify more advanced development later.
Does the program support purely descriptive basic biology studies?
The announcement emphasizes translation-oriented science. Proposals should be positioned to move beyond purely descriptive biology and toward interventions that could eventually be tested in people, even if the work funded under this announcement remains preclinical.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH Exploratory/Developmental Grant mechanism (R21).
What is the intent of an R21 award in this program?
The R21 is intended for early, high-impact, and potentially higher-risk projects that are still in conceptual or exploratory stages. Projects are generally expected to be focused and milestone-driven, producing feasibility or proof-of-principle data rather than completing a full mature development program.
How long can an R21 project last under this announcement?
Awards may last up to two years.
What is the maximum budget allowed?
Applicants may request up to $275,000 in direct costs total across the two-year period.
Are award amounts and the number of awards fixed?
No. The announcement indicates that award sizes and the number of awards may vary depending on scientific merit, project duration, and requested costs across the pool of applications.
Is this R21 renewable?
No. R21 awards under this program are not renewable. The expectation is that strong early findings would position a project for subsequent applications through other mechanisms.
How much funding did NIA set aside for this program?
NIA indicated an estimated $3.0 million in total costs in FY 2006 to support applications submitted in response to this program announcement.
How are applications reviewed?
Applications are reviewed using the standard NIH peer review process.
How is an application assigned to an NIH Institute or Center (IC)?
Applications are assigned to the appropriate participating NIH Institute or Center based on standard Public Health Service (PHS) referral guidelines and program relevance.
Who makes the final funding decision?
Funding decisions are made by the assigned NIH Institute or Center.
Is co-funding possible?
Yes. The announcement notes that, in some cases, meritorious applications may be co-funded by the assigned NIH institute together with the Institute for the Study of Aging (ISOA).
Who is eligible to apply?
Eligibility is broad and includes for-profit and nonprofit organizations, as well as public or private institutions such as universities, colleges, hospitals, and laboratories. Government entities are also eligible, including eligible federal agencies, state governments, and local governments.
Can foreign organizations apply?
Yes. Both domestic and foreign institutions may apply under this opportunity.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
Who can serve as the project lead (PI/PD)?
Any individual with the skills, knowledge, and resources needed to carry out the proposed research may work through an eligible institution to apply.
Does NIH encourage applications from underrepresented groups?
Yes. The announcement encourages applications from individuals from underrepresented racial and ethnic groups and from individuals with disabilities, consistent with NIH-wide policy goals.
Can an applicant submit more than one application?
Yes. Applicants may submit more than one application as long as each application is scientifically distinct and does not overlap substantially in aims, approach, or proposed outcomes.
When was this opportunity posted and what is its status?
The opportunity was posted on March 24, 2006, and it was later archived with an archive date of June 1, 2009.
Does the announcement have a single deadline?
No. The announcement notes multiple receipt dates rather than a single deadline.
What is the funding category and domain?
The opportunity is categorized as a discretionary grant in the health domain.
Are CFDA numbers associated with this program?
Yes. The announcement is associated with multiple CFDA numbers reflecting the cross-institute nature of the topic area, including aging research, neurosciences/neurological disorders, and mental health research.
Where can applicants find the full official announcement?
The full announcement is available at: http://grants.nih.gov/grants/guide/pa-files/PAS-06-261.html
Where is technical support directed for accessing the notice?
The source text indicates that general technical support for accessing the notice is routed through the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R03)
Previous opportunity: Exploratory/Developmental Clinical Research Grants in Obesity (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAS 06 261
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAS 06 261) also looked into and applied for these:
| Funding Opportunity |
|---|
| Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R03) Apply for PA 06 267 Funding Number: PA 06 267 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R21) Apply for PA 06 268 Funding Number: PA 06 268 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NEI Research Grant for Secondary Data Analysis (R21) Apply for PAR 06 326 Funding Number: PAR 06 326 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Womens Mental Health and Sex/Gender Differences Research (R21) Apply for PA 06 334 Funding Number: PA 06 334 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Planning Grants For Translational Research For The Prevention And Control Of Diabetes And Obesity (R34) Apply for PAR 06 358 Funding Number: PAR 06 358 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Cell Lineage and Developmental Studies in Hearing and Balance (R21) Apply for PA 06 365 Funding Number: PA 06 365 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Proteomics in Auditory Developmental and Disease Processes (R21) Apply for PA 06 366 Funding Number: PA 06 366 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIAID Clinical Trial Planning (R34) Grants Apply for PAR 06 384 Funding Number: PAR 06 384 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Proteins and Their Cellular Binding Partners (R21/R33) Apply for PA 06 388 Funding Number: PA 06 388 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21) Apply for PA 06 387 Funding Number: PA 06 387 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Human Biospecimen Resources for Aging Research (R03) Apply for PA 06 443 Funding Number: PA 06 443 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Research Opportunities in Stuttering (R21) Apply for PA 06 482 Funding Number: PA 06 482 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Oral Health Research Education Grants (R25) Apply for PAR 06 506 Funding Number: PAR 06 506 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Phased Innovation Awards in AIDS Vaccine Research (R21/R33) Apply for PA 06 519 Funding Number: PA 06 519 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunology of Biofilms (R21) Apply for PA 06 538 Funding Number: PA 06 538 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| MBRS Research Initiative for Scientific Enhancement (RISE) (R25) Apply for PAR 06 548 Funding Number: PAR 06 548 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Diversity (IMSD)(R25) Apply for PAR 06 553 Funding Number: PAR 06 553 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Studies of Bisphoshonate Therapy and Osteonecrosis of the Jaws (R21) Apply for PAR 06 556 Funding Number: PAR 06 556 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Community Based Participatory Research at NIMH (R21) Apply for PAR 07 004 Funding Number: PAR 07 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Demonstration and Dissemination Grants (R18) Apply for PA 07 017 Funding Number: PA 07 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAS 06 261", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.